Yanli Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yanli Ji has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Jizhi Wen
Institute of Blood Transfusion and Hematology, Guangzhou Blood Center Guangzhou Medical University Guangzhou China
10 shared publications Guangping Luo
Institute of Clinical Blood Transfusion, Guangzhou Blood Center Guangzhou China
8 shared publicationsLing Wei
Institute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou, China
8 shared publicationsShuangshuang Jia
Institute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou, China
7 shared publicationsJizhi Wen
Institute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou, China
6 shared publications- Ling Wei
Institute of Blood Transfusion and Hematology, Guangzhou Blood Center Guangzhou Medical University Guangzhou China
6 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Defining the Hybrid Glycophorin Haplotypes of the MNS Blood Group System Using Long-Read Sequencing
Ling Wei, M.M., Genghis H. Lopez, Ph.D., Robert L. Flower, Ph.D., Weiyi Fu, B.E., Jizhi Wen, M.S., Shuangshuang Jia, M.S., and Yanli Ji, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0280
- 6 November 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Open AccessDefining the Hybrid Glycophorin Haplotypes of the MNS Blood Group System Using Long-Read Sequencing
Ling Wei, M.M., Genghis H. Lopez, Ph.D., Robert L. Flower, Ph.D., Weiyi Fu, B.E., Jizhi Wen, M.S., Shuangshuang Jia, M.S., and Yanli Ji, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0280
- 5 August 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (9) , 1440-1450
International Forum on the Prevention of ABO Incompatible Red Blood Cell Transfusion: Summary
- 5 August 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (9) , 1440-1450
International Forum on the Prevention of ABO Incompatible Red Blood Cell Transfusion: Summary
- 5 August 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (9) , 1451-1485
International Forum on the Prevention of ABO Incompatible Red Blood Cell Transfusion: Responses
- 5 August 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (9) , 1451-1485
International Forum on the Prevention of ABO Incompatible Red Blood Cell Transfusion: Responses
- Open Access
- 12 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
An RHD gene variant, common in southern Chinese Han, involves a short 688 bp deletion and a long 21.8 kb insertion in the RHD exon 10 non-coding region, affecting the accuracy of red cell genotyping
Accurate typing of the D antigen is critical to provide guidance for blood transfusion and safe management of Rh-incompatible pregnancies. RHD genotyping a
- 12 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessAn RHD gene variant, common in southern Chinese Han, involves a short 688 bp deletion and a long 21.8 kb insertion in the RHD exon 10 non-coding region, affecting the accuracy of red cell genotyping
Accurate typing of the D antigen is critical to provide guidance for blood transfusion and safe management of Rh-incompatible pregnancies. RHD genotyping a
- 31 December 2025
- Published by Wiley in Transfusion
- Vol. 66 (3) , 628-630
Identification of a novel RHD*404T allele in a Chinese individual with variant D phenotype
- 31 December 2025
- Published by Wiley in Transfusion
- Vol. 66 (3) , 628-630
Identification of a novel RHD*404T allele in a Chinese individual with variant D phenotype
- 8 December 2025
- Published by Wiley in Transfusion
- Vol. 66 (1) , 280-282
Identification of a novel null allele A4GALT*02: c.457_463dup in one Chinese pedigree with the rare p phenotype and anti‐ PP1P k
- 8 December 2025
- Published by Wiley in Transfusion
- Vol. 66 (1) , 280-282
Identification of a novel null allele A4GALT*02: c.457_463dup in one Chinese pedigree with the rare p phenotype and anti‐ PP1P k
- 1 December 2025
- Published by Wiley in Vox Sanguinis
- Vol. 121 (2) , 202-212
International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology Report of Gothenburg, Barcelona and four virtual business meetings: Update on blood group systems
Background and Objectives: The International Society of Blood Transfusion (ISBT) Working Party (WP) on Red Cell Immunogenetics and Blood Group Terminology (RCI&BGT) held six business meetings between December 2021 and June 2024. This report describes the new blood group systems and antigens ratified during these meetings. Materials and Methods: Candidate systems and antigens were reviewed according to serological, genetic and biological evidence. This evidence was matched against defined criteria, and the acknowledged systems/antigens were assigned a unique identifier. Results: Four new systems, ER (ISBT 044), CD36 (ISBT 045), ATP11C (ISBT 046) and MAL (ISBT 047), were ratified. CD36 and ATP11C were de novo entries, while ER and MAL systems resolved the genetic basis for the Er and AnWj antigens. Thirteen antigens were added to existing systems: one each to LU (005), YT (011), SC (013), LW (016), KN (022), GLOB (028); an antithetical pair to KEL (006); two antigens to RHAG (030); and three to CTL2 (039). Two CTL2 antigens defined the hitherto unresolved antithetical antigens, Cs a /Cs b , whose genetic basis coincides with those of variants responsible for the HNA‐3a/3b neutrophil antigens, respectively. Conclusion: As of June 2024, the ISBT has acknowledged 47 blood group systems, comprising 366 antigens. The WP continues to ratify new systems and antigens, which are available on the ISBT website ( http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/ ).
- 1 December 2025
- Published by Wiley in Vox Sanguinis
- Vol. 121 (2) , 202-212
International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology Report of Gothenburg, Barcelona and four virtual business meetings: Update on blood group systems
Background and Objectives: The International Society of Blood Transfusion (ISBT) Working Party (WP) on Red Cell Immunogenetics and Blood Group Terminology (RCI&BGT) held six business meetings between December 2021 and June 2024. This report describes the new blood group systems and antigens ratified during these meetings. Materials and Methods: Candidate systems and antigens were reviewed according to serological, genetic and biological evidence. This evidence was matched against defined criteria, and the acknowledged systems/antigens were assigned a unique identifier. Results: Four new systems, ER (ISBT 044), CD36 (ISBT 045), ATP11C (ISBT 046) and MAL (ISBT 047), were ratified. CD36 and ATP11C were de novo entries, while ER and MAL systems resolved the genetic basis for the Er and AnWj antigens. Thirteen antigens were added to existing systems: one each to LU (005), YT (011), SC (013), LW (016), KN (022), GLOB (028); an antithetical pair to KEL (006); two antigens to RHAG (030); and three to CTL2 (039). Two CTL2 antigens defined the hitherto unresolved antithetical antigens, Cs a /Cs b , whose genetic basis coincides with those of variants responsible for the HNA‐3a/3b neutrophil antigens, respectively. Conclusion: As of June 2024, the ISBT has acknowledged 47 blood group systems, comprising 366 antigens. The WP continues to ratify new systems and antigens, which are available on the ISBT website ( http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/ ).
- 14 October 2025
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (3) , F236-F242
Effects of mother-infant ABO incompatibility on neonates: a cohort study in the Chinese population
Background It has traditionally been considered that mother-infant ABO incompatibility only causes mild haemolytic disease of the newborn (HDN). However, this view is inconsistent with clinical practice, and large-scale population-based data are lacking to investigate its effects on neonates. Methods Differences in hospitalisation rates and incidence rates of neonatal hyperbilirubinaemia (NHB) and anaemia among 47 679 Chinese liveborn neonates with different mother-infant ABO combinations, differences in the incidence of ABO-incompatible HDN (ABO-HDN) among neonates with O-B versus O-A mother-infant ABO incompatibility, and the contributions of ABO-HDN to the development of NHB and neonatal anaemia were analysed. Results Of the 47 679 liveborn neonates, neonates with mother-infant ABO incompatibility had higher rates of hospitalisation and incidence of NHB and anaemia. The hierarchy of the risk of mother-infant ABO incompatibility to the neonate was O-B > O-A > non-O-A/O-B incompatibility. Among neonates with O-B and O-A mother-infant ABO incompatibility, the ABO-HDN incidence rates were 15.27% (513/3359) and 11.33% (417/3680), respectively (95% CI 1.41 (1.23 to 1.62)), and the severe ABO-HDN incidence rates were 2.05% (69/3359) and 1.14% (42/3680), respectively (95% CI 1.82 (1.23 to 2.67)). Among the 7039 neonates with O-A/O-B mother-infant ABO incompatibility, ABO-HDN was an independent aetiological factor in 41.11% (666/1620) of the neonates with NHB, 70.27% (52/74) of the neonates with severe NHB, 42.34% (163/385) of the neonates with anaemia and 18.28% (17/93) of the neonates with severe anaemia. Conclusions Mother-infant ABO incompatibility often leads to severe HDN and is a dominant cause of NHB and neonatal anaemia, leading to significantly higher neonatal hospitalisation rates.
- 14 October 2025
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (3) , F236-F242
Effects of mother-infant ABO incompatibility on neonates: a cohort study in the Chinese population
Background It has traditionally been considered that mother-infant ABO incompatibility only causes mild haemolytic disease of the newborn (HDN). However, this view is inconsistent with clinical practice, and large-scale population-based data are lacking to investigate its effects on neonates. Methods Differences in hospitalisation rates and incidence rates of neonatal hyperbilirubinaemia (NHB) and anaemia among 47 679 Chinese liveborn neonates with different mother-infant ABO combinations, differences in the incidence of ABO-incompatible HDN (ABO-HDN) among neonates with O-B versus O-A mother-infant ABO incompatibility, and the contributions of ABO-HDN to the development of NHB and neonatal anaemia were analysed. Results Of the 47 679 liveborn neonates, neonates with mother-infant ABO incompatibility had higher rates of hospitalisation and incidence of NHB and anaemia. The hierarchy of the risk of mother-infant ABO incompatibility to the neonate was O-B > O-A > non-O-A/O-B incompatibility. Among neonates with O-B and O-A mother-infant ABO incompatibility, the ABO-HDN incidence rates were 15.27% (513/3359) and 11.33% (417/3680), respectively (95% CI 1.41 (1.23 to 1.62)), and the severe ABO-HDN incidence rates were 2.05% (69/3359) and 1.14% (42/3680), respectively (95% CI 1.82 (1.23 to 2.67)). Among the 7039 neonates with O-A/O-B mother-infant ABO incompatibility, ABO-HDN was an independent aetiological factor in 41.11% (666/1620) of the neonates with NHB, 70.27% (52/74) of the neonates with severe NHB, 42.34% (163/385) of the neonates with anaemia and 18.28% (17/93) of the neonates with severe anaemia. Conclusions Mother-infant ABO incompatibility often leads to severe HDN and is a dominant cause of NHB and neonatal anaemia, leading to significantly higher neonatal hospitalisation rates.
Identification of the Novel HLA‐E*01:154 Allele Using PolyseqOne and Oxford Nanopore Sequencing Technology
HLA‐E*01:154 differs from HLA‐E*01:01:01:01 by a single nonsynonymous nucleotide substitution in codon 199 of exon 3.
Identification of the Novel HLA‐E*01:154 Allele Using PolyseqOne and Oxford Nanopore Sequencing Technology
HLA‐E*01:154 differs from HLA‐E*01:01:01:01 by a single nonsynonymous nucleotide substitution in codon 199 of exon 3.
- 20 June 2025
- Published by Wiley in Transfusion
Combining computational approaches and functional analysis for characterizing the deleterious effect of RHD gene variants on splicing in the Chinese population
Background: Previous studies have shown that both intronic and exonic variants in RHD, the gene encoding the D antigen in the Rh blood group system, can alter mRNA splicing at the qualitative and/or quantitative level(s), thus resulting in a D variant phenotype. Here, we sought to further document this mechanism by analyzing extensively RHD variants found in the Chinese population.Study Design and Methods: From an in‐house database of whole exome sequencing of over 27,000 gDNA samples from Chinese individuals, as well as from ten Chinese individuals presenting with a D variant phenotype, RHD variants were selected in a first round of in silico approaches previously used (i.e., Alamut suite splicing module and ΔtESRseq score) for functional analysis by minigene splicing assay. All variants were further reevaluated subsequently by two contemporary bioinformatics tools, that is, SpliceAI and SPiP.Results: From the 269 single nucleotide variants (SNVs) included in the study, the 34 top‐score SNVs were selected as potential candidates for altering RHD splicing and comprehensively analyzed at the functional level. We demonstrated that eight SNVs, including three located within the consensus splice sites (c.336‐1G>C, c.801+2T>G, and c.940‐2delA), four in proximal intronic regulatory regions (c.149‐6G>A, c.939+5G>T, c.1154‐8T>G, and c.1227+5G>C), and one in exon (c.318G>A) alter splicing with a moderate to severe effect.Discussion: Our findings suggest that combining computational prediction with SpliceAI and/or SPiP using specific settings is an efficient approach (accuracy = 0.941) for selecting candidate SNVs that are prone to disrupt RHD splicing and alter D phenotype subsequently.
- 20 June 2025
- Published by Wiley in Transfusion
Combining computational approaches and functional analysis for characterizing the deleterious effect of RHD gene variants on splicing in the Chinese population
Background: Previous studies have shown that both intronic and exonic variants in RHD, the gene encoding the D antigen in the Rh blood group system, can alter mRNA splicing at the qualitative and/or quantitative level(s), thus resulting in a D variant phenotype. Here, we sought to further document this mechanism by analyzing extensively RHD variants found in the Chinese population.Study Design and Methods: From an in‐house database of whole exome sequencing of over 27,000 gDNA samples from Chinese individuals, as well as from ten Chinese individuals presenting with a D variant phenotype, RHD variants were selected in a first round of in silico approaches previously used (i.e., Alamut suite splicing module and ΔtESRseq score) for functional analysis by minigene splicing assay. All variants were further reevaluated subsequently by two contemporary bioinformatics tools, that is, SpliceAI and SPiP.Results: From the 269 single nucleotide variants (SNVs) included in the study, the 34 top‐score SNVs were selected as potential candidates for altering RHD splicing and comprehensively analyzed at the functional level. We demonstrated that eight SNVs, including three located within the consensus splice sites (c.336‐1G>C, c.801+2T>G, and c.940‐2delA), four in proximal intronic regulatory regions (c.149‐6G>A, c.939+5G>T, c.1154‐8T>G, and c.1227+5G>C), and one in exon (c.318G>A) alter splicing with a moderate to severe effect.Discussion: Our findings suggest that combining computational prediction with SpliceAI and/or SPiP using specific settings is an efficient approach (accuracy = 0.941) for selecting candidate SNVs that are prone to disrupt RHD splicing and alter D phenotype subsequently.